Genix Pharmaceuticals Corporation
GENPF · OTC
10/31/2024 | 10/31/2023 | 10/31/2022 | 10/31/2021 | |
|---|---|---|---|---|
| Revenue | $4 | $12 | $0 | $0 |
| % Growth | -67.2% | – | – | – |
| Cost of Goods Sold | $3 | $9 | $564 | $537 |
| Gross Profit | $1 | $3 | -$564 | -$537 |
| % Margin | 32% | 26.4% | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $173 | $274 | $432 | $1,118 |
| SG&A Expenses | $174 | $279 | $434 | $1,118 |
| Sales & Mktg Exp. | $1 | $5 | $2 | $0 |
| Other Operating Expenses | $68 | $605 | $0 | $0 |
| Operating Expenses | $242 | $884 | $1,031 | $1,655 |
| Operating Income | -$241 | -$881 | -$1,031 | -$1,653 |
| % Margin | -5,949.2% | -7,134.5% | – | – |
| Other Income/Exp. Net | $168 | -$3,515 | -$43 | -$579 |
| Pre-Tax Income | -$73 | -$4,396 | -$1,074 | -$1,653 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$73 | -$4,396 | -$1,074 | -$1,653 |
| % Margin | -1,806.9% | -35,600.3% | – | – |
| EPS | -0.001 | -0.074 | -0.018 | -0.028 |
| % Growth | 98.4% | -309.9% | 35.1% | – |
| EPS Diluted | -0.001 | -0.074 | -0.018 | -0.028 |
| Weighted Avg Shares Out | 59,244 | 59,224 | 59,224 | 59,224 |
| Weighted Avg Shares Out Dil | 59,224 | 59,224 | 59,224 | 59,224 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1 |
| Interest Expense | $121 | $52 | $12 | $4 |
| Depreciation & Amortization | $1 | $547 | $564 | $537 |
| EBITDA | $49 | -$3,796 | -$434 | -$1,117 |
| % Margin | 1,211.3% | -30,743.3% | – | – |